Bicycle Therapeutics (BCYC) Corporate presentation summary

Platform and pipeline overview

• Developing novel Bicycle® molecules, synthetic peptides capable of delivering diverse payloads to any target, based on Nobel Prize-winning science and protected by strong IP.

• Internal programs focus on oncology, with clinical-stage assets targeting historically undruggable cancer targets such as EphA2 and MT1-MMP.

• Radioligand pipeline addresses novel cancer targets, leveraging partnerships and a robust supply chain for next-generation radioisotopes.

• Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected runway into 2030.

Nuzefatide pevedotin clinical progress

• Nuzefatide pevedotin, a first-in-class EphA2-targeting Bicycle® Drug Conjugate, shows activity in multiple tumor types, including pancreatic and urothelial cancers.

• Demonstrates a differentiated safety profile with no bleeding events and fewer severe toxicities compared to antibody drug conjugates.

• Well tolerated as monotherapy and in combination with nivolumab, with most adverse events being low grade and few leading to discontinuation.

• Phase 2 trial in second-line+ pancreatic cancer is ongoing, with 8 mg/m² Q2W selected for optimal efficacy and safety.

Zelenectide pevedotin clinical progress

• Zelenectide pevedotin targets Nectin-4 and is designed to reduce toxicity while maintaining efficacy in metastatic urothelial cancer (mUC).

• In combination with pembrolizumab, shows response rates comparable to standard of care but with a more favorable safety profile, including fewer severe skin and neuropathy events.

• Monotherapy in 2L mUC demonstrates promising efficacy and is well tolerated, with most adverse events being Grade 1-2 and no treatment discontinuations at optimal dose.

• Randomized Phase 2 trial (Duravelo-2) underway, with results expected in 2H 2026.